<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-06-08T01:16:53Z</responseDate><request verb="GetRecord" identifier="oai:docta.ucm.es:20.500.14352/124078" metadataPrefix="marc">https://docta.ucm.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:docta.ucm.es:20.500.14352/124078</identifier><datestamp>2025-09-18T00:03:21Z</datestamp><setSpec>com_20.500.14352_14</setSpec><setSpec>col_20.500.14352_15</setSpec></header><metadata><record xmlns="http://www.loc.gov/MARC21/slim" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
   <leader>00925njm 22002777a 4500</leader>
   <datafield ind2=" " ind1=" " tag="042">
      <subfield code="a">dc</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Lorente Méndez, María del Carmen</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Alonso Miguel, Daniel</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="260">
      <subfield code="c">2025</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="520">
      <subfield code="a">Background: 
Effective management of otitis externa (OE) requires addressing all contributing factors to prevent chronicityand recurrence. Evidence on the long-term efficacy of topical corticosteroids in preventing recurrence and secondary infectionsremains limited.Objectives: This retrospective noncontrolled study evaluated the efficacy of hydrocortisone aceponate (HCA) in resolving non-infectious chronic or recurrent (CR)- OE with or without proliferative changes, and preventing recurrence of acute episodes andsecondary infections.Animals: A total of 63 owned dogs (115 ears) with unilateral or bilateral non-infectious CR- OE were included. Most ears wereenrolled after resolving infectious otitis, as persistent inflammation or recurrence required further management.Materials and Methods: Clinical records from two dermatology referral centres (February 2022–July 2023) were reviewed.Dogs were included if they had recurrent otitis for over a year (≥ 1 year) or chronic otitis (≥ 1 month). Otitis severity was assessedusing the Otitis Index Score (OTIS3) scale, and by grading stenosis and hyperplasia severity. Enrolled patients received HCA0.584 mg/mL at weight-adjusted doses. A reactive phase continued until OTIS3 &lt; 2, followed by a proactive phase with regimensadapted to otitis severity. Concurrent treatments were recorded.Results: Recurrence was not observed in 79.1% of ears (mean follow-up 202.6 days). Among 24 relapsed ears, 29.17% recurredafter treatment discontinuation. Higher recurrence was associated with stopping therapy (p &lt; 0.001) and recent bacterial otitis(p = 0.015). No adverse effects were noted.Conclusions and Clinical Relevance: The use of HCA appears to be an effective and safe option for reactive and proactivemanagement of non-infectious CRC- OE, reducing recurrences and improving patient and owner quality-of-life


Background: 
Effective management of otitis externa (OE) requires addressing all contributing factors to prevent chronicityand recurrence. Evidence on the long-term efficacy of topical corticosteroids in preventing recurrence and secondary infectionsremains limited.
Objectives:
This retrospective noncontrolled study evaluated the efficacy of hydrocortisone aceponate (HCA) in resolving non-infectious chronic or recurrent (CR)- OE with or without proliferative changes, and preventing recurrence of acute episodes andsecondary infections.
Animals: 
A total of 63 owned dogs (115 ears) with unilateral or bilateral non-infectious CR- OE were included. Most ears wereenrolled after resolving infectious otitis, as persistent inflammation or recurrence required further management.
Materials and Methods: 
Clinical records from two dermatology referral centres (February 2022–July 2023) were reviewed.Dogs were included if they had recurrent otitis for over a year (≥ 1 year) or chronic otitis (≥ 1 month). Otitis severity was assessedusing the Otitis Index Score (OTIS3) scale, and by grading stenosis and hyperplasia severity. Enrolled patients received HCA0.584 mg/mL at weight-adjusted doses. A reactive phase continued until OTIS3 &lt; 2, followed by a proactive phase with regimensadapted to otitis severity. Concurrent treatments were recorded.
Results:
Recurrence was not observed in 79.1% of ears (mean follow-up 202.6 days). Among 24 relapsed ears, 29.17% recurredafter treatment discontinuation. Higher recurrence was associated with stopping therapy (p &lt; 0.001) and recent bacterial otitis(p = 0.015). No adverse effects were noted.
Conclusions and Clinical Relevance: 
The use of HCA appears to be an effective and safe option for reactive and proactivemanagement of non-infectious CRC- OE, reducing recurrences and improving patient and owner quality-of-life</subfield>
   </datafield>
   <datafield ind1="8" ind2=" " tag="024">
      <subfield code="a">Lorente-Méndez, C., &amp; Alonso-Miguel, D. (2025). Hydrocortisone Aceponate for Chronic Otitis: Long-Term Efficacy. Veterinary dermatology, 10.1111/vde.70008. Advance online publication. https://doi.org/10.1111/vde.70008</subfield>
   </datafield>
   <datafield ind1="8" ind2=" " tag="024">
      <subfield code="a">0959-4493</subfield>
   </datafield>
   <datafield ind1="8" ind2=" " tag="024">
      <subfield code="a">10.1111/vde.70008</subfield>
   </datafield>
   <datafield ind1="8" ind2=" " tag="024">
      <subfield code="a">https://hdl.handle.net/20.500.14352/124078</subfield>
   </datafield>
   <datafield ind1="8" ind2=" " tag="024">
      <subfield code="a">1365-3164</subfield>
   </datafield>
   <datafield ind1="8" ind2=" " tag="024">
      <subfield code="a">https://doi.org/10.1111/vde.70008</subfield>
   </datafield>
   <datafield ind1="8" ind2=" " tag="024">
      <subfield code="a">40757500</subfield>
   </datafield>
   <datafield ind2="0" ind1="0" tag="245">
      <subfield code="a">Hydrocortisone Aceponate for Chronic Otitis: Long‐Term Efficacy</subfield>
   </datafield>
</record></metadata></record></GetRecord></OAI-PMH>